​

Arbutus Biopharma (ABUS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABUS Stock Forecast

Arbutus Biopharma (ABUS) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $8.50, with a high of $8.50 and a low of $8.50. This represents a 137.43% increase from the last price of $3.58.

$2 $3 $4 $5 $6 $7 $8 $9 High: $8.5 Avg: $8.5 Low: $8.5 Last Closed Price: $3.58

ABUS Stock Rating

Arbutus Biopharma stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 2 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 8 Strong Sell Sell Hold Buy Strong Buy

ABUS Price Target Upside V Benchmarks

TypeNameUpside
StockArbutus Biopharma137.43%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.58$3.58$3.58
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25121--4
May, 25121--4
Apr, 25121--4
Mar, 25121--4
Feb, 25221--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 17, 2022Ed ArceH.C. Wainwright$8.50$3.02181.46%137.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 05, 2024JefferiesBuyBuyhold
Jun 28, 2022JMP SecuritiesMarket OutperformMarket Outperformhold
Mar 17, 2022H.C. WainwrightBuyBuyhold
Feb 02, 2022JefferiesBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.86$-0.73$-0.46$-0.44$-0.38----
Avg Forecast$-0.98$-0.86$-0.45$-0.44$-0.39$-0.33$-0.41$-0.18$-0.23
High Forecast$-0.77$-0.68$-0.38$-0.43$-0.38$-0.29$-0.32$-0.14$-0.18
Low Forecast$-1.21$-1.07$-0.51$-0.45$-0.40$-0.41$-0.46$-0.20$-0.26
Surprise %-12.24%-15.12%2.22%--2.56%----

Revenue Forecast

$0 $13M $26M $39M $52M $65M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.91M$10.99M$39.02M$18.14M$6.17M----
Avg Forecast$6.52M$10.68M$38.96M$20.78M$6.19M$5.19M$8.42M$9.26M$56.41M
High Forecast$7.72M$12.63M$42.68M$21.03M$6.50M$5.45M$8.43M$9.28M$61.84M
Low Forecast$5.45M$8.92M$34.07M$20.36M$5.99M$4.97M$8.40M$9.24M$46.88M
Surprise %5.99%2.93%0.14%-12.71%-0.26%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.21M$-77.35M$-69.46M$-72.85M$-69.92M----
Avg Forecast$-162.64M$-143.06M$-75.01M$-72.85M$-64.39M$-57.64M$-64.83M$-28.46M$-38.17M
High Forecast$-127.91M$-112.51M$-62.76M$-70.75M$-62.74M$-48.03M$-53.10M$-23.31M$-29.79M
Low Forecast$-201.36M$-177.12M$-84.31M$-73.97M$-66.04M$-67.24M$-76.56M$-33.61M$-42.95M
Surprise %-59.90%-45.93%-7.41%-8.58%----

ABUS Forecast FAQ

Is Arbutus Biopharma stock a buy?

Arbutus Biopharma stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arbutus Biopharma is a favorable investment for most analysts.

What is Arbutus Biopharma's price target?

Arbutus Biopharma's price target, set by 10 Wall Street analysts, averages $8.5 over the next 12 months. The price target range spans from $8.5 at the low end to $8.5 at the high end, suggesting a potential 137.43% change from the previous closing price of $3.58.

How does Arbutus Biopharma stock forecast compare to its benchmarks?

Arbutus Biopharma's stock forecast shows a 137.43% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Arbutus Biopharma over the past three months?

  • June 2025: 25.00% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Arbutus Biopharma’s EPS forecast?

Arbutus Biopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.33, marking a -13.16% decrease from the reported $-0.38 in 2024. Estimates for the following years are $-0.41 in 2026, $-0.18 in 2027, and $-0.23 in 2028.

What is Arbutus Biopharma’s revenue forecast?

Arbutus Biopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $5.19M, reflecting a -15.88% decrease from the reported $6.17M in 2024. The forecast for 2026 is $8.42M, followed by $9.26M for 2027, and $56.41M for 2028.

What is Arbutus Biopharma’s net income forecast?

Arbutus Biopharma's net income forecast for the fiscal year ending in December 2025 stands at $-57.637M, representing a -17.57% decrease from the reported $-69.92M in 2024. Projections indicate $-64.831M in 2026, $-28.462M in 2027, and $-38.171M in 2028.